Somewhere online right now a video is ranking Mounjaro, Ozempic and Wegovy as first, second and third. It is satisfying to watch and almost useless as medicine, because the right injection depends on the person, not the ranking. The names sort into two medicines: Ozempic and Wegovy both contain semaglutide, while Mounjaro contains tirzepatide, and their approved uses, doses and availability differ by country.
The research does let us compare them fairly. In a 2025 head-to-head trial of 751 adults with obesity and no diabetes, tirzepatide produced greater average weight loss than semaglutide at 72 weeks, with gastrointestinal side effects in both groups. But a trial average is not a personal prescription, because one person's side effects, another's medical history, and a third's inability to get the medicine reliably all change the right answer, and cost and follow-up matter as much as any percentage.
This is why a responsible consultation looks nothing like a ranking video, and why the World Health Organization frames these as one part of a comprehensive plan rather than a standalone product. A doctor checks your blood glucose, blood pressure, kidney function, other medicines and eating pattern, and the plan that follows may include a medicine alongside diet, activity and follow-up.
What you can do
- Do not choose from a ranking video; book a consultation with a doctor who knows your full history.
- Expect the plan to include diet, activity and follow-up, not just an injection.
- Bring your other conditions, current medicines and goals, since they change which medicine, if any, is right for you.
- Write your questions first: what benefit is realistic, how are side effects handled, what is the cost over time, and what if supply is interrupted.
Important: The best choice is individual and clinical. In India these are prescription medicines, and no comparison video can decide for you.